Company: BIAF
Filing Date: 2025-08-13
Form Type: 8-K
Source: 0001641172-25-023488
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-13
Form: 8-K
Item: Item 3.01
Chunk 1
---
5, the Company’s
securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August
18, 2025.

In
addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and
pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities.

The
Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s
securities pending the decision of the Panel. Hearings are typically scheduled to occur approximately 30-45 days after the date of the
hearing request. At the hearing, the Company intends to present its views and its plans to regain compliance with the Minimum Bid Price
Requirement and the Continued Listing Equity Requirement to the Panel. There can be no assurance that the Company will be able to evidence
compliance with the Minimum Bid Price Rule, the Continued Listing Equity Requirement or any other applicable requirements for continued
listing on The Nasdaq Capital Market prior to the hearing. It is the Company’s understanding that the Panel typically issues its
decision within 30 days after the hearing.

There
can be no assurance that the Panel will grant the Company any extension period within which to regain compliance with the Minimum Bid
Price Requirement and the Continued Listing Equity Requirement, or if any such extension period is granted, that the Company will regain
compliance with the Minimum Bid Price Requirement and the Continued Listing Equity Requirement within such extension period, or that
the Company will be successful in otherwise maintaining the listing of its common stock on The Nasdaq Capital Market.

This
report contains forward-looking statements, including, but not limited to, the timing of the hearing and the timing of the decision of
the Panel. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied
by such forward-looking statements. In particular, the hearing may be scheduled, and the Panel may issue a decision, more quickly than
expected based on the typical time periods in published Nasdaq guidance, which shorter timeline(s) may be unfavorable for the Company
and the continued listing of the Company’s common stock on The Nasdaq Capital Market. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this report. The Company undert